Loading data for REPL — first visit, this takes a few seconds.

Alert

Replimune Group Inc. (REPL)

NasdaqGS: REPL · Real-Time Price · USD

14.77

+0.72 (5.12%)

At close: Aug 21, 2026, 8:00 PM

14.67

-0.69%

After-hours: 7:57 PM

The price, the headline numbers and the latest news, in one place.

5.12% (1D)

No data available

Bid	10.67
Market Cap	1.39B
Revenue (ttm)	n/a
Net Income (ttm)	-297.01M
	0.90
	-3.15
	n/a
	-8.03
P/B (ttm)	11.74
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Ask	17.79
Volume	2,944,017
Avg. Volume (20D)	5,824,801
Open	13.86
Previous Close	14.05
Day's Range	13.81 - 14.98
52-Week Range	1.50 - 15.71
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About REPL

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) a...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 20, 2018

Employees 465

Stock Exchange NasdaqGS

Ticker Symbol REPL

Website https://www.replimune.com

Full Company Profile

Financial Performance

In 2026, Replimune's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -313.94M, an increase of 26.95%.

Financial Statements

Earnings Surprise

Replimune has released their quarterly earnings on Aug 14, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.72 exceeds estimates by 0.05, with 24.21% YoY growth.

Next Earnings Release

Replimune Group Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · Simply Wall St.

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

Replimune Group (NasdaqGS:REPL) received FDA accelerated approval for TUDRIQEV (RP1) in combination with nivolumab to treat advanced cutaneous melanoma after anti PD 1 therapy. This marks the first FD...

1 week ago · Stocktwits

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?

AbCellera, Replimune and Airbnb reached fresh highs as strong drug data, new funding and better-than-expected earnings boosted investor confidence.

1 week ago · Stocktwits

REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’

The firm priced about 9.7 million shares at $12.06 each, in line with Friday’s closing price.

1 week ago · Barrons.com

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

2 weeks ago · Stocktwits

Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line

Replimune’s Tudriqev was granted accelerated approval by the FDA earlier this week, following two prior complete response letters and a 10-3 advisory committee vote in late July recommending the thera...

Page 1 of 2

Replimune Group Inc. (REPL)